Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

63 results about "Platelet Aggregation Inhibition" patented technology

About Platelet Aggregation Inhibition: Platelet Aggregation Inhibitors decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation, where anticoagulants have little effect. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Method for evaluating chemical composition of Rosa xanthina on basis of antithrombotic spectrum-effect relationship

ActiveCN108195989AComprehensive and accurate spectrum effect basisClear chemical compositionComponent separationMathematical modelSeparation technology
The invention discloses a method for evaluating chemical composition of Rosa xanthina on the basis of antithrombotic spectrum-effect relationship. The method comprises the following steps: preparing extract of different polar components of the Rosa xanthina with a modern separation technology; establishing fingerprint of extract of each component with high-performance liquid chromatography, and calibrating characteristic peaks; evaluating antithrombotic activity of different extract on the basis of platelet aggregation inhibition rate, prothrombin time, thrombin time and activated partial thromboplastin time as indexes; substituting fingerprint characteristic peak data and pharmacodynamical activity data into a mathematical model for spectrum-effect correlation analysis, and evaluating pharmacodynamical activity of the characteristic peaks. With adoption of the method for evaluating the chemical composition of the Rosa xanthina on the basis of the antithrombotic spectrum-effect relationship, the antithrombotic chemical composition in the Rosa xanthina can be evaluated rapidly and accurately, a scientific and effective method is provided for research of pharmacodynamic material basis and quality control of the Rosa xanthina, and reference is provided for further development of Rosa xanthina drugs or health care products for treating thrombotic diseases.
Owner:山西省医药与生命科学研究院

Application of ginseng total sub-glycoside combination, ginseng prosapogenin or ginseng protosaponin in preparation of medicines for treating Meniere's syndrome

The invention relates to the field of medicines, and particularly relates to an application of a ginseng total sub-glycoside combination, ginseng prosapogenin or ginseng protosaponin in the preparation of medicines for treating tinnitus, dizziness and Meniere's syndrome. Plants for preparing the ginseng total sub-glycoside medicine combination are panax plants, and are preferably selected from at least one of ginseng, pseudo-ginseng, panax japonicus, American gingseng and Korean ginseng. The ginseng total sub-glycoside combination is a mixture of ginsenoside partially hydrolyzed and a degradation product, namely secondary saponin, part of glycosyl of which is removed. The physiological activity of the ginseng total sub-glycoside combination is greatly enhanced, and the ginseng total sub-glycoside combination has the physiological activities such as blood vessel expansion, heart dynamic enhancement and platelet aggregation inhibition. The ginseng total sub-glycoside combination, the ginseng prosapogenin or the ginseng protosaponin is used for treating the Meniere's syndrome, is definite in curative effect and has high effective rate, small individual difference and high safety without side effects.
Owner:SHANGHAI HONGYITANG BIOPHARM CO LTD

Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same

The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
Owner:HANALL PHARMA CO LTD

Anti-HIV aedes albopictus protein with platelet aggregation inhibiting function and preparation method of anti-HIV aedes albopictus protein

The invention relates to an anti-HIV aedes albopictus protein with a platelet aggregation inhibiting function. An amino acid sequence of the anti-HIV aedes albopictus protein is shown as SEQ ID NO:1. A preparation method of the anti-HIV aedes albopictus protein comprises the following steps: purifying total RNA of aedes albopictus salivary glands and amplifying so as to obtain total cDNA, then amplifying genes of the total cDNA taken as a template and cloning the genes into a prokaryotic expression vector, carrying out inducible expression via IPTG, carrying out denaturation and renaturation folding on an expressed inclusion body, then filtering the inclusion body via a gel, and carrying out separation and purification on the inclusion body by ion exchange chromatography so as to obtain the anti-HIV aedes albopictus protein. The anti-HIV aedes albopictus protein has the activities of inhibiting the proliferation of the HIV in cells and the platelet aggregation induced by multiple agonists, and has the advantages of no cytotoxicity and strong anti-HIV specificity. Thus, the anti-HIV aedes albopictus protein can be used for preparing medicines for resisting AIDS (Acquired Immune Deficiency Syndrome) and related diseases.
Owner:SOUTHERN MEDICAL UNIVERSITY

Compound traditional Chinese medicine composition for preventing and treating disturbance of coronary microcirculation and animal experiment method

The invention relates to a compound traditional Chinese medicine composition for preventing and treating the disturbance of coronary microcirculation and an animal experiment method. The compound traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: radix astragali, angelica, scorpio and scolopendra. The preparation method of thecompound traditional Chinese medicine composition comprises the following steps: preparing the traditional Chinese medicines in parts by weight: radix astragali, angelica, scorpio and scolopendra, soaking the traditional Chinese medicines into water which is 15 times of the total weight of the traditional Chinese medicines for 40 minutes, carrying out decoction with strong fire for 70 minutes forthe first time, adding water which is 10 times of the total weight of the traditional Chinese medicines, carrying out decoction with soft fire for 50 minutes for the second time, adding water which is6 times of the total weight of the traditional Chinese medicines, carrying out decoction with soft fire for 50 minutes for the third time, combining three decoction solutions, filtering by virtue ofgauze, concentrating to 150ml through water bath at 100 DEG C, and storing the combined decoction solution in a refrigerator at 4 DEG C, so as to obtain the finished product. The compound traditionalChinese medicine composition has the efficacies of expanding blood vessels, inhibiting platelet aggregation and inflammation and the like, is capable of improving the disturbance of coronary microcirculation and can be applied to the technical field of the traditional Chinese medicine.
Owner:LIAONING UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products